Global Continuous Bioprocessing Market Size and Share Analysis 2023-2028

Market Overview

The Global Continuous Bioprocessing Market is poised for substantial expansion, with an anticipated increase from USD 163.7 million in 2023 to USD 466.0 million by 2028, registering a commendable CAGR of 23.27% during the forecast period (2023-2028).

Continuous manufacturing of a production unit is defined as the capability to process uninterrupted flow inputs over an extended period. The output may either be continuous or divided into smaller packets generated in a circular manner.

Product Type

Market Report

No. of Pages


Release Date

April 2023

Base Year


Forecast Period


Market Size

USD 466 Mn incremental growth between 2022 and 2027

Market Segments

Product, Application, End-User, and Geography



No. of Companies Mentioned


Recent times have witnessed countries grappling with the formidable threat of COVID-19. As per the World Health Organization (WHO), COVID-19 is an infectious disease, with most infected individuals experiencing mild to moderate respiratory illness. Pharmaceutical and biotechnological companies have diverted their resources in research and development (R&D) departments towards identifying new molecules or leads for COVID-19 treatment. This shift has impacted the research and development activities of biopharmaceuticals for other chronic diseases. The pandemic’s early phase, marked by lockdown measures, trade restrictions, and high infection rates, severely affected pharmaceutical and biotechnology companies, particularly their R&D operations, leading to delays of over six months in clinical and other types of trials.

The study titled Impact of COVID19 on Operational Activities of Manufacturing Organizations—A Case Study and Industry 4.0-Based Survive-Stabilise-Sustainability (3S) Framework, published in March 2021, highlighted that local authorities’ restrictions had the highest impact on operational activities, followed by unavailability of transport and workers. Scarcity of raw materials, increased workload, and reduced working days also significantly affected biopharmaceutical organizations. Furthermore, machine failures, overproduction, and insufficient production to meet demand had additional adverse effects on operational activities, further impacting the market.

Several factors are fueling the growth of the studied market, including the increasing adoption of continuous processing, technological advancements in the continuous processing domain, and growing demand for biopharmaceuticals. Additionally, investments and government initiatives aimed at bolstering biomanufacturing will contribute positively to market growth.

Continuous bioprocessing is emerging as a leading form of biomanufacturing production due to its scalability in both clinical production and commercialization. Leveraging flexible infrastructures, such as single-use flow paths and small surgical vessels with consistent bioreactor sizes, results in significant cost savings and facilitates smoother technology transfer operations while maintaining quality profiles. Moreover, the escalating burden of chronic diseases, such as cancer, neurological disorders, cardiovascular diseases, and rare diseases, is driving the demand for biopharmaceuticals, thereby propelling the continuous bioprocessing market. For example, according to GLOBOCAN 2020 statistics, approximately 19,292,789 people were diagnosed with cancer in 2020, and this number is projected to reach 30.2 million by 2040, underscoring the rising global burden of cancer and the subsequent demand for biosimilars.

Furthermore, rising investments in the studied market are poised to foster lucrative growth. A case in point is the strategic investment made by Gamma Biosciences in September 2021, which involved investing in Nirrin Technologies—a provider of next-generation sensors and analytics for real-time, in-process monitoring and analysis in upstream and downstream bioprocessing applications, including continuous processing for the biopharma and life science industries. However, the market’s growth may face hurdles due to stringent regulations pertaining to continuous bioprocessing and high equipment costs.

Market Segmentation

The market is segmented based on various factors, including Product, Application, End-User, and Geography

Segmentation by Product
Filtration Systems and Consumables
Chromatography Systems and Consumables
Others (Incubators and Shakers, Cell Culture Media, Buffers and Reagents and Consumables)

Segmentation by Application
Research and Development

Segmentation by End-User
Pharmaceutical and Biotechnology Companies
CDMOs and CROs
Academic and Research Institutes

Segmentation by Geography
North America – United States, Canada, Mexico
Europe – United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America – Brazil, Argentina, and Rest of Latin America
Middle East and Africa – GCC, South Africa, and Rest of Middle East and Africa

During the study period, the research and development segment of the continuous bioprocessing market is anticipated to experience substantial growth. This growth can be attributed to several key factors, including the increasing expenditure on research and development, growing demand for biopharmaceuticals, the establishment of new facilities, and technological advancements within the segment.

An illustrative example of the sector’s progress is evident in Transcenta’s announcement in March 2021. The company achieved a remarkable breakthrough in its continuous perfusion cell culture platform, achieving a volumetric productivity of over 6 g/L per day. Furthermore, this productivity improvement resulted in a 15-fold increase in drug substance output per year compared to the conventional fed-batch process, substantially enhancing the productivity of single-use bioreactors. Such advancements and the resultant increase in productivity through continuous bioprocessing are expected to drive significant market growth.

Additionally, collaborative efforts, such as the partnership between The United States Pharmacopeia (USP) and Phlow Corp. in March 2021, aim to establish new laboratories for developing test methods and standards for continuous manufacturing. This initiative intends to foster wider adoption of continuous manufacturing by generic drug and pharmaceutical manufacturers through product development, tech transfer, and drug application filings. Moreover, the establishment of continuous biomanufacturing facilities dedicated to research and development activities will further contribute to market growth. Therefore, considering these factors, the research and development segment is expected to play a pivotal role in driving the overall growth of the market.

The North American continuous processing market is primarily driven by factors such as the escalating burden of chronic diseases, continuous product launches, strategic initiatives undertaken by market players, the establishment of continuous bioprocessing facilities, and technological advancements within the sector.

In North America, the United States is anticipated to hold a significant share of the studied market during the study period. For instance, estimations from the 2022 American Cancer Society, Inc. project approximately 236,740 new cases of lung cancer and 79,000 new cases of kidney cancer, with 13,920 deaths reported from kidney cancer in 2022. The prevalence of such chronic diseases is expected to drive the demand for biosimilar and other biopharmaceuticals, thereby propelling the growth of the continuous bioprocessing market.

In March 2022, Phlow Corp. entered into strategic alliances with Virginia Commonwealth University’s (VCU) Medicines for All Institute and AMPAC Fine Chemicals to provide contract continuous manufacturing research and development (R&D) services for small molecule pharmaceutical products. These partnerships are poised to boost the operation of continuous manufacturing facilities, further stimulating market growth.

A study published in January 2022, titled A Comparative Investment Analysis of Batch Versus Continuous Pharmaceutical Manufacturing Technologies, indicated the potential economic attractiveness of continuous manufacturing for oral solid dosage pharmaceuticals within the United States, surpassing foreign manufacturing of those products. These findings are expected to contribute significantly to the adoption of continuous manufacturing processes in the country, consequently fostering market growth. In conclusion, considering the aforementioned factors, the continuous bioprocessing market is anticipated to witness lucrative growth during the study period.

Competitive Landscape

The continuous bioprocessing market is characterized by significant competition and is comprised of several prominent industry participants. In relation to market share, a select group of major players currently hold commanding positions within the market. Notable among these dominant companies are 3M, Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Eppendorf SE, among others.

Key companies profiled in this report include 3M Company, Thermo Fisher Scientific Inc., Merck Kgaa, Sartorius Group, Eppendorf SE, Danaher Corporation, Bio-Rad LaboratoriesInc., Repligen Corporation, Bionet, Dover Corporation (Colder Products Company), Fujifilm Corporation, Getinge AB.

Recent Industry Developments

During the month of February in the year 2022, CellulaREvolution successfully raised a substantial amount of GBP 1.75 million from a consortium of notable investors. This funding round was prominently led by Happiness Capital. The infusion of capital is intended to expedite the company’s ongoing research and development efforts while also bolstering their commercial team. These measures have been taken in preparation for the imminent launch of their groundbreaking continuous cell culture technology.

In January 2022, WuXi Biologics demonstrated its commitment to advancing biomanufacturing capabilities by making a significant investment of EUR 325 million. This substantial financial commitment has been allocated towards the establishment of a cutting-edge biomanufacturing facility. The facility is strategically designed to facilitate continuous bioprocessing, thus elevating the efficiency and productivity of their biotechnological operations.

Key Questions Answered

What is the study period of the Global Continuous Bioprocessing Market?
The Global Continuous Bioprocessing Market is studied from 2018 to 2028.

What is the growth rate of the Global Continuous Bioprocessing Market?
The Global Continuous Bioprocessing Market is experiencing a growth rate of 23.27% over the next 5 years.

What is the size of the Global Continuous Bioprocessing Market?
The Global Continuous Bioprocessing Market is projected to reach USD 163.7 million in 2023 and is expected to grow at a CAGR of 23.27% to reach USD 466.0 million by 2028.

Which region has the highest growth rate in the Global Continuous Bioprocessing Market?
Asia-Pacific is witnessing the highest CAGR growth over the period of 2018 to 2028.

Which region has the largest share in the Global Continuous Bioprocessing Market?
As of 2021, North America holds the highest market share.

Who are the key players in the Global Continuous Bioprocessing Market?
The major companies operating in the Global Continuous Bioprocessing Market are 3M, Thermo Fisher Scientific, Merck KGaA, Sartorius AG, and Eppendorf SE.

Original price was: USD 4,750.Current price is: USD 2,850.

Want to customize this report? Our industry specialist will collaborate with you to deliver tailored data within a limited timeframe.
Scroll to Top

Request Free Sample Report

Global Continuous Bioprocessing Market Size and Share Analysis 2023-2028

Please fill out our form and we will get back to you.


Global Continuous Bioprocessing Market Size and Share Analysis 2023-2028

Please fill out our form and we will get back to you.